Browse Arkansas Code titles and sections
20-77-138. Medications approved by United States Food and Drug Administration for tobacco cessation coverage.
Arkansas Code — all titles (historical 2020) · legal_authorities
20-77-138. Medications approved by United States Food and Drug Administration for tobacco cessation coverage.
(a) The Department of Human Services shall ensure that the Arkansas Medicaid Program covers medications approved by the United States Food and Drug Administration for tobacco cessation, including without limitation:
(1) Nicotine replacement therapy patches;
(2) Nicotine replacement therapy gum;
(3) Nicotine replacement therapy lozenges;
(4) Nicotine replacement therapy nasal spray;
(5) Nicotine replacement therapy inhalers;
(6) Bupropion; and
(7) Varenicline.
(b) Prior authorization shall not be required for coverage of medications described in subsection (a) of this section.
Source: Arkansas Code — historical release 78 (November 6, 2020) · 20-77-138
Stored review status: Historical 2020-11-06 source release; later amendments not reconciled; machine-extracted, not independently legally reviewed; source heading status: text_in_historical_source. A text match is a research starting point; applicability is not established.
Issuing source page ↗
Authority boundary: historical statutory source snapshot not current law.
Open the recorded source website ↗
Record provenance
Stable record: arkansas_code:legal_authorities:20-77-138
Source file: gov.ar.code.title.20.odt
Pages: Not recorded – Not recorded
Passage SHA-256: 27df1ba8bf29e0e554b2a7386e5869cfdd70139b22a2b8752586ff311eef33a3
Source location: content.xml paragraph 35951
Stored source content
20-77-138. Medications approved by United States Food and Drug Administration for tobacco cessation coverage.
(a) The Department of Human Services shall ensure that the Arkansas Medicaid Program covers medications approved by the United States Food and Drug Administration for tobacco cessation, including without limitation:
(1) Nicotine replacement therapy patches;
(2) Nicotine replacement therapy gum;
(3) Nicotine replacement therapy lozenges;
(4) Nicotine replacement therapy nasal spray;
(5) Nicotine replacement therapy inhalers;
(6) Bupropion; and
(7) Varenicline.
(b) Prior authorization shall not be required for coverage of medications described in subsection (a) of this section.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
No explicit source connection was found. This does not mean there are no relevant authorities.